生脉饮对阿霉素致Wistar大鼠心肌损伤的心脏保护作用
研究生脉饮对阿霉素诱导的Wistar大鼠慢性心力衰竭模型的心肌保护作用,采用HPLC定量成分,ELISA测炎症因子,IHC和RT-PCR测COL-IV及MMPs。结果显示生脉饮可降低TNF-α、IL-6、MMPs和COL-IV,减轻心肌病理改变,高剂量组效果与卡托普利相似。
要点
- 生脉饮可降低阿霉素心衰大鼠的TNF-α和IL-6水平。
- 高剂量生脉饮降低心肌COL-IV表达,与卡托普利类似。
- 生脉饮可能通过抑制炎症和纤维化延缓心衰进展。
核心结论
- 生脉饮可能通过下调IL-6和TNF-α、抑制MMPs和COL-IV过度表达,延缓慢性心衰进展。
- 生脉饮与卡托普利在治疗阿霉素诱导心肌损伤方面具有相似疗效。
研究设计与样本
- 研究为动物实验,采用Wistar大鼠建立阿霉素诱导的慢性心力衰竭模型。
- 阿霉素腹腔注射7周,剂量为2 mg/kg体重。
- 共180只大鼠随机分为6组:对照组、心衰模型组、卡托普利组、生脉饮高剂量组、中剂量组和低剂量组。
- 卡托普利剂量为0.625 mg/kg,生脉饮高、中、低剂量分别为90、45、22.5 mg/kg,给药7周。
主要发现
- 生脉饮中人参皂苷Rg1、麦冬皂苷D、麦冬皂苷D'和五味子素的含量分别为每克25.63±3.42 mg、11.00±1.17 mg、7.02±0.51 mg和25.31±4.28 mg。
- 与心衰模型组相比,四个给药组TNF-α水平均显著降低(p < .01)。
- 除生脉饮低剂量组外,其他三个给药组IL-6水平也显著降低(p < .01)。
- 高剂量生脉饮组COL-IV表达显著降低(p < .05)。
- 免疫组化结果证实生脉饮和卡托普利均能显著降低心脏MMPs表达。
临床怎么用
- 生脉饮可能作为慢性心衰的辅助治疗选择,尤其适用于气阴两虚证。
- 高剂量生脉饮在抑制心肌纤维化方面显示出与卡托普利相似的潜力。
局限性
- 研究为动物实验,结果不能直接外推到临床。
- 样本量、具体P值(除部分p < .01和p < .05外)及置信区间未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sheng Mai Yin (SMY), a well-known Chinese herbal medicine, is widely used to treat cardiac diseases characterized by the deficiency of Qi and Yin syndrome in China. SMY-based treatment has been derived from Traditional Chinese Medicine (TCM), officially recorded in the Chinese Pharmacopoeia. PURPOSE: We aimed to clarify whether SMY attenuates myocardial injury induced by adriamycin in Wistar rats with chronic heart failure (CHF). METHODS: To quantify ginsenoside Rg1, ophiopogonin D, ophiopogonin D', schisandrin by HPLC. To establish CHF animal model, adriamycin was intraperitoneally injected in Wistar rats for 7 weeks at a dose of 2 mg/kg body weight. Overall, 180 rats were randomly assigned to six groups: control, CHF model, captopril (positive control), high dose (HSMY), medium dose (MSMY), and low dose (LSMY). Experimental rats were fed 0.625 mg/kg captopril and 90 mg/kg, 45 mg/kg, and 22.5 mg/kg SMY, respectively, over 7 weeks. The inflammatory cytokines TNF-α and IL-6 were measured using ELISA. Matrix metalloproteinases (MMPs) were identified using immunohistochemistry (IHC). Both IHC and RT-PCR were used for quantification of COL-IV expression levels in the heart tissues. Scanning electron microscopy (SEM) was used for the visualization of myocardium morphology. RESULTS: The concentration of ginsenoside Rg1, ophiopogonin D, ophiopogonin D' and schisandrin in SMY was found to be 25.63 ± 3.42 mg, 11.00 ± 1.17 mg, 7.02 ± 0.51 mg, and 25.31 ± 4.28 mg per gram of SMY, respectively. Compared with CHF model group, TNF-α levels were significantly lower (p < .01) in the four drug-administered groups. Moreover, except in the SYM low dose group, IL-6 levels in the other 3 drug-administered groups were also significantly reduced (p < .01). COL-IV expression was also significantly reduced on treatment with high SYM dose (p < .05). IHC results confirmed that SMY and captopril significantly reduced MMPs expression in the heart. CONCLUSION: SMY could control or slow CHF progression by suppressing pathological changes in the myocardium in CHF models. This could be attributed at least partly to the downregulation of IL-6 and TNF-α and inhibition of overexpression of MMPs and COL-IV, which significantly relieved the cardiac-linked pathologies, decreased the risk of myocardial fibrosis, and inhibited cardiac remodeling. These findings suggested that SMY and captopril have similar efficacy for the treatment of adriamycin-induced myocardial injury. In addition, Chinese herbal preparation SMY may play a role in the treatment of cardiac diseases.
引用
- Zhang K, Zhang J, Wang X, et al. Cardioprotection of Sheng Mai Yin a classic formula on adriamycin induced myocardial injury in Wistar rats. Phytomedicine. 2017. PMID: 29425641. doi:10.1016/j.phymed.2017.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。